Prediction of commonly used antibiotics-induced coagulation disorders by the establishment and application of clinical model based on Mutations in clotting factor VII

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000037351

Enrollment

Unknown

Registered

2020-08-28

Start date

2021-01-01

Completion date

Unknown

Last updated

2020-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antibacterial drugs-induced coagulation disorders

Interventions

Grouped according to whether coagulation disorders occur:Nil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Irrespective of age or gender; 2.Hospital stay >= 5 days; 3.Received cefoperazone, levofloxacin, tigecycline monotherapy or combination therapy; 4.Read and fully understand the patient instructions and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients with severe hepatic and renal insufficiency; 2.Patients with existing clotting dysfunction or clotting disorder; 3.Lacking coagulation function before or after treatment; 4.Pregnant or breastfeeding women; 5.Others (Such as incomplete medical records).

Design outcomes

Primary

Measure	Time frame
Clotting factor VII genotype;Age;Gender;department;Medical history;Dose;Frequency;Duration;Concomitant medications;History of adverse drug reactions;	—

Secondary

Measure	Time frame
WBC;CRP;PCT;ALT;AST;TBIL;EGFR;	—

Countries

China

Contacts

Public ContactDong-Jie Li

Shanghai Tenth People's Hospital

ldjbio@126.com+86 18917687625

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026